510 related articles for article (PubMed ID: 33482338)
1. Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?
Favoino E; Prete M; Catacchio G; Ruscitti P; Navarini L; Giacomelli R; Perosa F
Autoimmun Rev; 2021 Mar; 20(3):102750. PubMed ID: 33482338
[TBL] [Abstract][Full Text] [Related]
2. Janus kinase-signal transducers and activators of transcription cell signaling in Spondyloarthritis: rationale and evidence for JAK inhibition.
Raychaudhuri S; Cheema KS; Raychaudhuri SK; Raychaudhuri SP
Curr Opin Rheumatol; 2021 Jul; 33(4):348-355. PubMed ID: 34014847
[TBL] [Abstract][Full Text] [Related]
3. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
4. The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Bechman K; Yates M; Galloway JB
Pharmacol Res; 2019 Sep; 147():104392. PubMed ID: 31401212
[TBL] [Abstract][Full Text] [Related]
5. Molecular dissection of Janus kinases as drug targets for inflammatory diseases.
Kwon S
Front Immunol; 2022; 13():1075192. PubMed ID: 36569926
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase inhibitors in autoimmune bullous diseases.
Huang D; Zhang Y; Kong L; Lu J; Shi Y
Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signaling pathway in non-infectious uveitis.
Su Y; Tao T; Liu X; Su W
Biochem Pharmacol; 2022 Oct; 204():115236. PubMed ID: 36041544
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
[TBL] [Abstract][Full Text] [Related]
10. JAK-STAT Pathway: A Novel Target to Tackle Viral Infections.
Ezeonwumelu IJ; Garcia-Vidal E; Ballana E
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960648
[TBL] [Abstract][Full Text] [Related]
11. Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions.
Ryguła I; Pikiewicz W; Kaminiów K
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138551
[TBL] [Abstract][Full Text] [Related]
12. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT inhibitors in Immune mediated diseases: An Overview.
Shah RJ; Banerjee S; Raychaudhuri S; Raychaudhuri SP
Indian J Dermatol Venereol Leprol; 2023; 89(5):691-699. PubMed ID: 37609730
[TBL] [Abstract][Full Text] [Related]
14. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
15. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
[TBL] [Abstract][Full Text] [Related]
16. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Banerjee S; Biehl A; Gadina M; Hasni S; Schwartz DM
Drugs; 2017 Apr; 77(5):521-546. PubMed ID: 28255960
[TBL] [Abstract][Full Text] [Related]
17. JAK inhibitors and autoimmune rheumatic diseases.
Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
[TBL] [Abstract][Full Text] [Related]
18. The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin P; Xu X; Deng C; Liu S; Wang Y; Zhou X; Ma H; Wei D; Sun S
Int Immunopharmacol; 2020 Mar; 80():106210. PubMed ID: 31972425
[TBL] [Abstract][Full Text] [Related]
19. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer.
Xue C; Yao Q; Gu X; Shi Q; Yuan X; Chu Q; Bao Z; Lu J; Li L
Signal Transduct Target Ther; 2023 May; 8(1):204. PubMed ID: 37208335
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]